REPLIGEN CORP Financial Summary

Quick Answer

REPLIGEN CORP reported Total Revenue of $141.24 million for fiscal year 2017.

REPLIGEN CORP — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue
Net Income $48.89M
+291.6%
-$25.51M
-171.7%
$35.60M
-80.9%
$185.96M
+45.0%
$128.29M
+114.1%
$59.93M
+179.9%
Diluted EPS $0.86
+287.0%
-$0.46
-173.0%
$0.63
-80.6%
$3.24
+44.6%
$2.24
+101.8%
$1.11
+152.3%
Total Assets $2.95B
+4.2%
$2.83B
-0.1%
$2.83B
+12.1%
$2.52B
+7.1%
$2.36B
+23.9%
$1.90B
+35.9%
Cash and Equivalents $566.02M
-25.3%
$757.36M
+0.8%
$751.32M
+43.5%
$523.46M
-13.3%
$603.81M
-15.8%
$717.29M
+35.7%
Long-Term Debt $542.21M
+3.2%
$525.57M
Stockholders Equity $2.11B
+6.8%
$1.97B
+0.4%
$1.96B
+2.8%
$1.91B
+9.2%
$1.75B
+14.4%
$1.53B
+44.3%
R&D Expense $54.18M
+25.4%
$43.20M
+1.1%
$42.72M
-2.8%
$43.94M
+28.2%
$34.27M
+69.8%
$20.18M
+3.8%
Operating Income $55.17M
+257.1%
-$35.11M
-173.6%
$47.70M
-78.8%
$224.67M
+34.3%
$167.25M
+139.5%
$69.82M
+93.5%
Shares Outstanding 56.33M
+0.4%
56.09M
+0.6%
55.77M
+0.4%
55.56M
+0.4%
55.32M
+1.0%
54.76M
+5.2%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue March 31, 2018 $44.83M +46.6% +22.6%
Net Income September 30, 2025 $14.91M +2380.0% +0.3%
Diluted EPS September 30, 2025 $0.26 +2700.0% +0.0%
Total Assets September 30, 2025 $2.92B +3.3% +0.8%
Cash and Equivalents September 30, 2025 $748.75M -4.5% +5.6%
Long-Term Debt September 30, 2025 $537.93M +2.4%
Stockholders Equity September 30, 2025 $2.08B +3.3% +1.0%
R&D Expense September 30, 2025 $14.18M +46.0% +1.6%
Operating Income September 30, 2025 $16.82M +314.8% +21.1%
Shares Outstanding September 30, 2025 56.28M +0.5% +0.1%
  • REPLIGEN CORP reported Total Revenue of $141.24 million for fiscal year 2017.
  • REPLIGEN CORP showed an increase of +35.1% in Total Revenue compared to the prior fiscal year.
  • REPLIGEN CORP reported Net Income of $48.89 million for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +291.6% in Net Income compared to the prior fiscal year.
  • REPLIGEN CORP reported Diluted EPS of $0.86 per share for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +287.0% in Diluted EPS compared to the prior fiscal year.
  • REPLIGEN CORP reported Total Assets of $2.95 billion for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +4.2% in Total Assets compared to the prior fiscal year.
  • REPLIGEN CORP reported Cash and Equivalents of $566.02 million for fiscal year 2025.
  • REPLIGEN CORP showed a decrease of -25.3% in Cash and Equivalents compared to the prior fiscal year.
  • REPLIGEN CORP reported Long-Term Debt of $542.21 million for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +3.2% in Long-Term Debt compared to the prior fiscal year.
  • REPLIGEN CORP reported Stockholders Equity of $2.11 billion for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +6.8% in Stockholders Equity compared to the prior fiscal year.
  • REPLIGEN CORP reported R&D Expense of $54.18 million for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +25.4% in R&D Expense compared to the prior fiscal year.
  • REPLIGEN CORP reported Operating Income of $55.17 million for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +257.1% in Operating Income compared to the prior fiscal year.
  • REPLIGEN CORP reported Shares Outstanding of 56.33 million shares for fiscal year 2025.
  • REPLIGEN CORP showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment